A number of other brokerages have also recently weighed in on DRNA. ValuEngine upgraded shares of Dicerna Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Wednesday, November 6th. Chardan Capital reiterated a “buy” rating and set a $18.00 price target on shares of Dicerna Pharmaceuticals in a research note on Tuesday, August 13th. Leerink Swann increased their price target on shares of Dicerna Pharmaceuticals from $22.00 to $26.00 in a research note on Friday, November 1st. HC Wainwright set a $22.00 price target on shares of Dicerna Pharmaceuticals and gave the stock a “buy” rating in a research note on Monday, August 26th. Finally, Zacks Investment Research upgraded shares of Dicerna Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, November 5th. One equities research analyst has rated the stock with a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the company’s stock. Dicerna Pharmaceuticals has a consensus rating of “Buy” and an average target price of $22.50.
Shares of Dicerna Pharmaceuticals stock traded up $0.24 during trading hours on Friday, hitting $17.93. The company had a trading volume of 474,130 shares, compared to its average volume of 465,197. The company’s 50-day moving average is $15.64 and its two-hundred day moving average is $14.28. Dicerna Pharmaceuticals has a twelve month low of $9.31 and a twelve month high of $18.39. The company has a debt-to-equity ratio of 0.01, a current ratio of 3.65 and a quick ratio of 3.65. The company has a market cap of $1.17 billion, a P/E ratio of -14.94 and a beta of 2.29.
Dicerna Pharmaceuticals (NASDAQ:DRNA) last issued its quarterly earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.45) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.30) by ($0.15). The business had revenue of $8.04 million for the quarter, compared to analyst estimates of $11.70 million. Dicerna Pharmaceuticals had a negative return on equity of 50.30% and a negative net margin of 737.93%. Sell-side analysts expect that Dicerna Pharmaceuticals will post -1.39 EPS for the current year.
In other news, COO James B. Weissman sold 15,000 shares of the firm’s stock in a transaction on Thursday, October 31st. The shares were sold at an average price of $18.00, for a total value of $270,000.00. Following the completion of the sale, the chief operating officer now owns 29,704 shares in the company, valued at approximately $534,672. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider James B. Weissman sold 14,680 shares of the firm’s stock in a transaction on Friday, August 23rd. The stock was sold at an average price of $13.07, for a total transaction of $191,867.60. Following the completion of the sale, the insider now owns 9,800 shares of the company’s stock, valued at approximately $128,086. The disclosure for this sale can be found here. In the last quarter, insiders have sold 42,180 shares of company stock valued at $686,868. 21.28% of the stock is owned by company insiders.
Several hedge funds have recently added to or reduced their stakes in DRNA. TD Asset Management Inc. lifted its stake in shares of Dicerna Pharmaceuticals by 44.6% in the 2nd quarter. TD Asset Management Inc. now owns 53,480 shares of the biopharmaceutical company’s stock worth $842,000 after acquiring an additional 16,500 shares during the period. DekaBank Deutsche Girozentrale acquired a new stake in shares of Dicerna Pharmaceuticals in the 2nd quarter worth $724,000. Candriam Luxembourg S.C.A. lifted its stake in shares of Dicerna Pharmaceuticals by 7.2% in the 2nd quarter. Candriam Luxembourg S.C.A. now owns 479,800 shares of the biopharmaceutical company’s stock worth $9,860,000 after acquiring an additional 32,300 shares during the period. Swiss National Bank lifted its stake in shares of Dicerna Pharmaceuticals by 9.5% in the 2nd quarter. Swiss National Bank now owns 87,600 shares of the biopharmaceutical company’s stock worth $1,380,000 after acquiring an additional 7,600 shares during the period. Finally, State Board of Administration of Florida Retirement System lifted its stake in shares of Dicerna Pharmaceuticals by 17.0% in the 2nd quarter. State Board of Administration of Florida Retirement System now owns 21,334 shares of the biopharmaceutical company’s stock worth $336,000 after acquiring an additional 3,100 shares during the period. Institutional investors own 83.16% of the company’s stock.
Dicerna Pharmaceuticals Company Profile
Dicerna Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery and development of ribonucleic acid interference (RNAi)-based pharmaceuticals. The company develops pharmaceuticals using its GalXC RNAi platform for the treatment of diseases involving the liver, including rare diseases, viral infectious diseases, chronic liver diseases, and cardiovascular diseases.
Further Reading: How to execute a trade ex-dividend strategy?
Receive News & Ratings for Dicerna Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dicerna Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.